Skip to main contentSkip to navigation
Sirius Investors

ZNTL Stock: Zentalis Pharmaceuticals, Inc. Stock Price, Analysis & Insights

Get live ZNTL stock price $3.58, comprehensive Zentalis Pharmaceuticals, Inc. stock analysis, charts, news, and expert forecast. Real-time ZNTL stock data and investment insights.

3.58
0.00%Today
ZNTLZentalis Pharmaceuticals, Inc. • NASDAQ Global Market • Healthcare
Market Cap
254.85M
Volume
440.31K
52W High
6.95
52W Low
1.13

Loading chart data...

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Zentalis Pharmaceuticals, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on the discovery and advancement of small molecule therapies designed to treat a range of cancers. The company's pipeline features two primary...

Company Information

CEO
Julie Eastland
Sector
Healthcare
Industry
Biotechnology
Employees
166

Contact Information

Address
1359 Broadway
Country
US

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Higher growth potential with elevated volatility (Beta: 1.97)

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Zentalis Pharmaceuticals, Inc. shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Zentalis Pharmaceuticals, Inc.
  • Investors should consider how Zentalis Pharmaceuticals, Inc. fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

254.85M

P/E Ratio (TTM)

-2.06

Beta

1.97

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.